Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [41] Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
    Mark Jesus M Magbanua
    Eduardo V Sosa
    Janet H Scott
    Jeff Simko
    Colin Collins
    Dan Pinkel
    Charles J Ryan
    John W Park
    BMC Cancer, 12
  • [42] PSMA theragnostics for metastatic castration resistant prostate cancer
    Song, Hong
    Guja, Kip E.
    Iagaru, Andrei
    TRANSLATIONAL ONCOLOGY, 2022, 22
  • [43] Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
    Merseburger, Axel S.
    Waldron, Nick
    Ribal, Maria J.
    Heidenreich, Axel
    Perner, Sven
    Fizazi, Karim
    Sternberg, Cora N.
    Mateo, Joaquin
    Wirth, Manfred P.
    Castro, Elena
    Olmos, David
    Petrylak, Daniel P.
    Chowdhury, Simon
    EUROPEAN UROLOGY, 2021, 79 (04) : 519 - 529
  • [44] The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer
    Le Guevelou, Jennifer
    Cuccia, Francesco
    Flippot, Ronan
    Ferrera, Giuseppe
    Terlizzi, Mario
    Zilli, Thomas
    De Crevoisier, Renaud
    Hannoun-Levi, Jean-Michel
    Supiot, Stephane
    Sargos, Paul
    Pasquier, David
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
  • [45] Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
    Chen, William S.
    Aggarwal, Rahul
    Zhang, Li
    Zhao, Shuang G.
    Thomas, George, V
    Beer, Tomasz M.
    Quigley, David A.
    Foye, Adam
    Playdle, Denise
    Huang, Jiaoti
    Lloyd, Paul
    Lu, Eric
    Sun, Duanchen
    Guan, Xiangnan
    Rettig, Matthew
    Gleave, Martin
    Evans, Christopher P.
    Youngren, Jack
    True, Lawrence
    Lara, Primo N.
    Kothari, Vishal
    Xia, Zheng
    Chi, Kim N.
    Reiter, Robert E.
    Maher, Christopher A.
    Feng, Felix Y.
    Small, Eric J.
    Alumkal, Joshi J.
    EUROPEAN UROLOGY, 2019, 76 (05) : 562 - 571
  • [46] Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
    Fallara, Giuseppe
    Robesti, Daniele
    Raggi, Daniele
    Montorsi, Francesco
    Necchi, Andrea
    Cooperberg, Matthew R.
    Malavaud, Bernard
    Ploussard, Guillaume
    Martini, Alberto
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 52 : 40 - 43
  • [47] Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
    Menssouri, Naoual
    Poiraudeau, Loic
    Helissey, Carole
    Bigot, Ludovic
    Sabio, Jonathan
    Ibrahim, Tony
    Pobel, Cedric
    Nicotra, Claudio
    Ngo-Camus, Maud
    Lacroix, Ludovic
    Rouleau, Etienne
    Tselikas, Lambros
    Chauchereau, Anne
    Blanc-Durand, Felix
    Bernard-Tessier, Alice
    Patrikidou, Anna
    Naoun, Natacha
    Flippot, Ronan
    Colomba, Emeline
    Fuerea, Alina
    Albiges, Laurence
    Lavaud, Pernelle
    van de Wiel, Paul
    den Biezen, Eveline
    Wesseling-Rozendaal, Yvonne
    Ponce, Santiago
    Michiels, Stefan
    Massard, Christophe
    Gautheret, Daniel
    Barlesi, Fabrice
    Andre, Fabrice
    Besse, Benjamin
    Scoazec, Jean-Yves
    Friboulet, Luc
    Fizazi, Karim
    Loriot, Yohann
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4504 - 4517
  • [48] Adverse clinical outcomes and distinct genomic phenotype of BRCA-deficient metastatic castration-resistant prostate cancer (mCRPC)
    Fettke, Heidi
    Dai, Chao
    Kwan, Edmond M.
    Zheng, Tiantian
    Tan, Winston
    Du, P.
    Ng, Nicole
    Bukszynska, Patricia
    Docanto, Maria
    Graham, L. K.
    Mahon, Kate
    Horvath, Lisa G.
    Jia, Shidong
    Kohli, Manish
    Azad, Arun A.
    CANCER RESEARCH, 2023, 83 (07)
  • [49] Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
    Adashek, Jacob J.
    Jain, Rohit K.
    Zhang, Jingsong
    CELLS, 2019, 8 (08)
  • [50] COSTS AND CLINICAL OUTCOMES IN THE MANAGEMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN GREECE
    Rentzeperi-Michalakou, E.
    Kani, C.
    Souliotis, K.
    Aravantinos, G.
    Samantas, E.
    Ardavanis, A.
    Koumakis, G.
    Markantonis, S.
    VALUE IN HEALTH, 2016, 19 (07) : A758 - A758
12345